The Cooper Companies/$COO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About The Cooper Companies
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
- Ticker
- $COO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15,000
- Headquarters
- San Ramon, United States
- Website
- www.coopercos.com
COO Metrics
BasicAdvanced
$11B
19.12
$2.90
0.82
-
Price and volume
Market cap
$11B
Beta
0.82
52-week high
$89.83
52-week low
$51.01
Average daily volume
4.9M
Financial strength
Current ratio
1.222
Quick ratio
0.506
Long term debt to equity
0.261
Total debt to equity
0.336
Interest coverage (TTM)
5.87%
Profitability
EBITDA (TTM)
907.5
Gross margin (TTM)
65.35%
Net profit margin (TTM)
13.46%
Operating margin (TTM)
12.36%
Effective tax rate (TTM)
-23.33%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
2.73%
Return on equity (TTM)
6.84%
Valuation
Price to earnings (TTM)
19.122
Price to revenue (TTM)
2.551
Price to book
1.27
Price to tangible book (TTM)
3.51
Price to free cash flow (TTM)
16.004
Free cash flow yield (TTM)
6.25%
Free cash flow per share (TTM)
3.471
Growth
Revenue change (TTM)
4.73%
Earnings per share change (TTM)
42.40%
3-year revenue growth (CAGR)
6.43%
10-year revenue growth (CAGR)
8.33%
3-year earnings per share growth (CAGR)
28.16%
10-year earnings per share growth (CAGR)
8.57%
What the Analysts think about COO
Analyst ratings (Buy, Hold, Sell) for The Cooper Companies stock.
Analyst projections of the future price of The Cooper Companies stock.
Bulls say / Bears say
CooperVision’s premium MyDay range is gaining traction: the franchise delivered double-digit growth in EMEA and double-digit consumption growth in the Americas. Further MyDay launches, including a toric multifocal lens, could extend this momentum. (Stock Analysis)
Fertility is providing a growth engine in CooperSurgical, with revenue up 5% organically in the third quarter. Management expects continued demand, while the segment’s genomics and clinic wins support its growth prospects. (GlobeNewswire)
Cash generation and capital returns were strong in the third quarter: free cash flow reached a record $273 million, up 66%, and Cooper repurchased $339 million of shares. This gives the company capacity to keep returning capital while investing in its businesses. (GlobeNewswire)
CooperVision’s near-term performance is weak: third-quarter revenue was flat as the company cut US channel inventory, and its fourth-quarter outlook calls for organic revenue to fall 2% or be flat. The inventory reset is expected to keep weighing on results in the near term. (GlobeNewswire)
Margins face near-term pressure from foreign exchange headwinds, lower tariff refunds and higher commercial investment. Management expects these factors to weigh on gross and operating margins in the fourth quarter. (The Motley Fool)
Paragard faces a new competitive threat: a rival non-hormonal IUD has been approved and acquired, with a launch expected in the future. That could weaken the position of a product whose market standing was cited as a factor in lower CooperSurgical sale valuations. (SEC, Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
COO Financial Performance
Revenues and expenses
COO Earnings Performance
Company profitability
Upcoming events
No upcoming events
COO News
AllArticlesVideos
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
Newsfile Corp2 days ago
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
Newsfile Corp3 days ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
Newsfile Corp4 days ago
Funds containing COO
AllUSDEURGBP
Fund name | Fund size | $COO weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.39% |
iShares Ageing Population€AGED | €822M | 0.39% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.20% |
Xtrackers S&P 500 Equal Weight$XDEW | $16B | 0.18% |
Xtrackers S&P 500 Equal Weight£XDWE | $16B | 0.18% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.